PRIME-CKD aims to identify, validate and implement biomarkers for kidney disease progression and thus improve the treatment response of individual patients to drugs that enhance kidney outcomes into clinical practice.

In a New York Times article, Dr. Subramaniam Pennathur sheds light on the groundbreaking benefits of semaglutide, offering new hope to patients battling chronic kidney disease and Type 2 diabetes.